SA News • May. 29, 2013
There are no Focus articles on GNMSY.
There are no Transcripts on GNMSY.
May. 29, 2013, 3:28 PMGlaxoSmithKline (GSK -3%) says a combination of ARZERRA and chlorambucil has met its primary endpoint of improving progression free survival times (versus treatment with chlorambucil alone) in a pivotal Phase 3 trial with partner Genmab (GNMSF.PK). No unexpected safety issues were encountered. (PR) | Comment!
Aug. 30, 2012, 8:16 AMJ&J (JNJ) unit Janssen Biotech buys the global licensing rights to cancer agent daratumumab from Danish biotech Genmab in a deal that could eventually be worth over $1.1B. Janssen is paying $55M upfront and will make further payments following the achievement of development, regulatory and sales milestones. J&J is also investing $80M in Genmab in return for a 10.7% stake. (PR) | Comment!
There are no StockTalks on this stock yet.
Other News & PR